Aquestive Therapeutics Inc (AQST)
3.24
+0.15
(+4.85%)
USD |
NASDAQ |
May 13, 10:21
Aquestive Therapeutics Research and Development Expense (Quarterly): 5.932M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.932M |
| December 31, 2023 | 2.888M |
| September 30, 2023 | 3.196M |
| June 30, 2023 | 3.473M |
| March 31, 2023 | 3.547M |
| December 31, 2022 | 4.278M |
| September 30, 2022 | 3.232M |
| June 30, 2022 | 5.198M |
| March 31, 2022 | 4.773M |
| December 31, 2021 | 4.40M |
| September 30, 2021 | 4.726M |
| June 30, 2021 | 4.262M |
| March 31, 2021 | 3.659M |
| December 31, 2020 | 4.425M |
| September 30, 2020 | 7.26M |
| Date | Value |
|---|---|
| June 30, 2020 | 3.847M |
| March 31, 2020 | 4.354M |
| December 31, 2019 | 3.057M |
| September 30, 2019 | 5.063M |
| June 30, 2019 | 8.151M |
| March 31, 2019 | 4.303M |
| December 31, 2018 | 5.683M |
| September 30, 2018 | 4.534M |
| June 30, 2018 | 7.994M |
| March 31, 2018 | 4.901M |
| December 31, 2017 | 6.271M |
| September 30, 2017 | 5.684M |
| June 30, 2017 | 4.837M |
| March 31, 2017 | 5.343M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.888M
Minimum
Dec 2023
8.151M
Maximum
Jun 2019
4.486M
Average
4.316M
Median
Research and Development Expense (Quarterly) Benchmarks
| Lifecore Biomedical Inc | 2.116M |
| Harrow Inc | 3.336M |
| Akebia Therapeutics Inc | 9.865M |
| 89bio Inc | 47.43M |
| Geron Corp | 29.37M |